Global Information
회사소개 | 문의 | 비교리스트

생식기 사마귀 : 시장 인사이트, 역학, 시장 예측(-2030년)

Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 05월 상품코드 934328
페이지 정보 영문 131 Pages 배송안내 1-2일 (영업일 기준)
US $ 3,750 ₩ 5,421,000 PDF (Single User License)
US $ 7,500 ₩ 10,843,000 PDF (Site License)
US $ 11,250 ₩ 16,265,000 PDF (Global License)

생식기 사마귀 : 시장 인사이트, 역학, 시장 예측(-2030년) Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast - 2030
발행일 : 2020년 05월 페이지 정보 : 영문 131 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 생식기 사마귀(Genital Warts) 관련 시장을 조사했으며, 시장 개요, 치료와 관리, 백신, 역학과 환자수, 관련 조직, 사례 연구, 시판약, 새로운 치료법, 시장 성장 촉진요인과 저해요인, 시장 접근과 상환 등의 정보를 제공합니다.


제1장 주요 조사 결과

제2장 생식기 사마귀 개요

제3장 생식기 사마귀 관련 시장 SWOT 분석

제4장 질환 배경과 개요

  • 서론
  • 박물학
  • 원인과 위험
  • 증상
  • 병태생리
  • 임상 소견
  • 미치료 HVP 감염의 합병증
  • 진단

제5장 치료와 관리

제6장 백신

  • Gardasil : Merck
  • Cervarix : GlaxoSmithKline
  • 비교
  • 차이

제7장 역학과 환자 인구

  • 주요 조사 결과
  • 각국의 역학
  • 미국
    • 가정과 근거
    • 미국에서의 발생률
    • 미국에서의 성별 특정 진단 증례
    • 미국에서의 연령별 진단 증례
    • 미국에서의 해부학적 위치

제8장 미충족 요구

제9장 생식기 사마귀와 관련된 조직

제10장 사례 연구

  • 증례 보고
  • 첨규콘딜롬 증례 보고

제11장 시판약

  • Zyclara : Graceway Pharmaceuticals
    • 제품 설명
    • 기타 개발 활동
    • 안전성과 유효성
  • Veregen(Polyphenon E) : Aresus Pharma

제12장 새로운 치료법

  • Cantharidin(VP-102): Verrica Pharmaceuticals
    • 제품 설명
    • 제품 개발 활동
    • 임상 개발
    • 안전성과 유효성
  • Berdazimer sodium(SB206): Novan Inc.
  • SR-T100 Gel: G&E Herbal Biotechnology Co. LTD

제13장 기타 유망한 약제

  • Onconase(Ranpirnase): Tamir Biotechnology
    • 제품 설명
    • 기타 개발 활동
    • 임상 개발
    • 안전성과 유효성
  • Santalum album cream(VIR007): Santalis Healthcare

제14장 중지된 제품 개발

  • Teslexivir(BTA-074): Vaxart
    • 제품 설명
    • 기타 개발 활동
    • 안전성과 유효성

제15장 미국 시장 분석

  • 주요 조사 결과
  • 시장 전망
  • 시장 규모

제16장 시장 성장 촉진요인

제17장 시장 성장 저해요인

제18장 시장 접근과 상환

제19장 부록

  • 참고문헌
  • 조사 방법

제20장 DelveInsight의 서비스 내용

제21장 면책사항

제22장 DelveInsight 소개

KSM 20.06.01

List of Tables

  • Table 1: Summary of Genital Warts (GWs) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Low-risk HPV versus High-risk HPV
  • Table 3: Treatment Modalities
  • Table 4: Treatments and their Advantages
  • Table 5: Enhancing the efficacy of imiquimod
  • Table 6: Gardasil versus Cervarix
  • Table 7: Diagnosed Incident Population of GWs in the United States (2017-2030)
  • Table 8: Gender Specific Diagnosed Cases of GWs in the United States (2017-2030)
  • Table 9: Age Specific Diagnosed Cases of GWs in the United States (2017-2030)
  • Table 10: Anatomical Location of GWs in the United States (2017-2030)
  • Table 11: Organizations contributing toward Genital Warts
  • Table 12: VP-102, Clinical Trial Description, 2020
  • Table 13: SB206, Clinical Trial Description, 2020
  • Table 14: SR-T100, Clinical Trial Description, 2020
  • Table 15: Ranpirnase, Clinical Trial Description 2020
  • Table 16: VIR007, Clinical Trial Description 2020
  • Table 17: The US Market of GWs in USD Million (2017-2030)
  • Table 18: The US GWs Market Size by Therapy in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Different Types of Warts
  • Figure 3: HPV Structure and Function
  • Figure 4: HPV Structure and Function
  • Figure 5: Infection by HPV
  • Figure 6: Checklist for Initial Consultation
  • Figure 7: Checklist for providing Treatment
  • Figure 8: Treatment Algorithm
  • Figure 9: Newer Simplified Treatment Algorithm
  • Figure 10: Algorithm for Treatment Selection
  • Figure 11: Algorithm for Treatment Selection in Pregnant Patients
  • Figure 12: Diagnosed Incidence of GWs in the United States (2017-2030)
  • Figure 13: Gender Specific Diagnosed Cases of GWs in the United States (2017-2030)
  • Figure 14: Age Specific Diagnosed Cases of GWs in the United States (2017-2030)
  • Figure 15: Anatomical Location of GWs in the United States (2017-2030)
  • Figure 16: Unmet needs for GWs
  • Figure 17: Market Size of GWs in the United States, USD Millions (2017-2030)
  • Figure 18: The U.S. GWs Market Size by Therapy USD Million (2017-2030)
  • Figure 19: Market drivers for GWs
  • Figure 20: Market Barriers for GWs

DelveInsight's 'Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GWs in the United States.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Warts (GWs) from 2017 to 2030. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States

Study Period: 2017-2030

Genital Warts (GWs) - Disease Understanding and Treatment Algorithm

Genital warts (GWs) are transmitted by having sexual contact with someone who already has them, and may be found on the outside of genitals. Some types, which cause cancer, result in the growth of lesions on a woman's cervix. It is possible to get genital warts, HPV infection, even if they are not visible. They look like flesh-colored bumps that have a cauliflower-like appearance, and are usually flat, papular, or pedunculated growths on the genital mucosa, occurring in clusters. They can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual contact with an infected person. Potentially cancer-causing HPV strains are spread by sexual intercourse, anal sex, and oral sex. Moreover, genital warts is also known as anogenital warts (AGWs) or condylomata acuminata.

The current options available for the treatment of GWs are largely centered upon removal of the warty growth rather than elimination of the underlying viral infection. Common treatments include 1) topical therapeutic agents; 2) physical removal of warts with cryotherapy, electrocautery or lasers; or 3) photodynamic therapy. As recommended in literature as first-line therapy, imiquimod was most commonly prescribed. Furthermore, in the second treatment cycle, current literature describes a combined approach of topicals and physician-performed procedures as having a lower recurrence rate of CA. The third therapeutic attempt focuses on surgical procedures and has showed a high success rate.

The DelveInsight Genital Warts (GWs) market report gives the thorough understanding of the Genital Warts by including details such as disease definition, classification, symptoms, etiology, pathophysiology, complications, biomarkers and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Genital Warts in the US.

Genital Warts Epidemiology

The Genital Warts (GWs) epidemiology division provides the insights about historical and current patient pool and forecasted trend for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Incidence of GWs, Gender-specific Cases, Age-specific Cases of Genital Warts, HPV type associated with GWs and Anatomical Location of Warts) in the United States from 2017-2030.

According to DelveInsight, the total number of diagnosed incident cases of Genital Warts (GWs) in the US was found to be 4,65,000 in the year 2017.

Genital Warts Drug Chapters

This segment of the Genital Warts report encloses the detailed analysis of marketed drugs and early stage (Phase-I and Phase-II) pipeline drugs along with other promising candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

A multidisciplinary treatment approach is usually followed internationally for the management of GWs and the market consequently can be divided into segments based on revenue generated by therapies which include pain control, management of HPV infection and management of other complications. However, there are important points to be noted such as the fact that there are some curative treatment options at present and Vaccines are main Preventive treatment therapies used.

Genital Warts Market Outlook

The Genital Warts market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Genital Warts in the US was found to be USD 694 Million in 2017, and is expected to increase during the course of the study period (2017-2030).

Genital Warts Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Genital Warts Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Genital Warts Report Key Strengths

  • 11 Year Forecast
  • The US Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Genital Warts Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Genital Warts market
  • Organize sales and marketing efforts by identifying the best opportunities for Genital Warts market, and to understand the future market competition in the Genital Warts market.

Table of Contents

1 Key Insights

2 Executive Summary of GWs

3 SWOT Analysis for GWs

4 Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Natural History
  • 4.3. Causes and Risks
  • 4.4. Symptoms
  • 4.5. Pathophysiology
  • 4.6. Clinical Presentation
  • 4.7. Complications of Untreated HVP Infection
  • 4.8. Diagnosis

5 Treatment and Management

6 Vaccines

  • 6.1. Gardasil: Merck
  • 6.2. Cervarix: GlaxoSmithKline
  • 6.3. Comparison
  • 6.4. Differences

7 Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Country Wise-Epidemiology
  • 7.3. United States
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Diagnosed incidence of GWs in the United States
    • 7.3.3. Gender Specific Diagnosed Cases of GWs in the United States
    • 7.3.4. Age Specific Diagnosed Cases of GWs in the United States
    • 7.3.5. Anatomical Location of Genital Warts in the United States

8 Unmet Needs

9 Organizations related to GWs

10 Case Studies

  • 10.1. A Case Report of Genital Warts
  • 10.2. A Case Report of Condyloma Acuminata

11 Marketed Drugs

  • 11.1. Zyclara: Graceway Pharmaceuticals
    • 11.1.1. Product Description
    • 11.1.2. Other Developmental Activities
    • 11.1.3. Safety and Efficacy
  • 11.2. Veregen (Polyphenon E): Aresus Pharma
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Safety and Efficacy

12 Emerging Therapies

  • 12.1. Cantharidin (VP-102): Verrica Pharmaceuticals
    • 12.1.1. Product Description
    • 12.1.2. Product Development Activities
    • 12.1.3. Clinical Development
      • Clinical Trials Information
    • 12.1.4. Safety and Efficacy
  • 12.2. Berdazimer sodium (SB206): Novan Inc.
    • 12.2.1. Product Description
    • 12.2.2. Product Development Activities
    • 12.2.3. Clinical Development
      • Clinical Trials Information
    • 12.2.4. Safety and Efficacy
  • 12.3. SR-T100 Gel: G & E Herbal Biotechnology Co. LTD
    • 12.3.1. Product Description
    • 12.3.2. Product Development Activities
    • 12.3.3. Clinical Development
      • Clinical Trials Information
    • 12.3.4. Safety and Efficacy

13 Other Promising Drugs

  • 13.1. Onconase (Ranpirnase): Tamir Biotechnology
    • 13.1.1. Product Description
    • 13.1.2. Other Development Activities
    • 13.1.3. Clinical Development
      • Clinical Trials Information
    • 13.1.4. Safety and Efficacy
  • 13.2. Santalum album cream (VIR007): Santalis Healthcare
    • 13.2.1. Product Description
    • 13.2.2. Other Development Activities
    • 13.2.3. Clinical Development
      • Clinical Trials Information
    • 13.2.4. Safety and Efficacy

14 Discontinued Product Development

  • 14.1. Teslexivir (BTA-074): Vaxart
    • 14.1.1. Product Description
    • 14.1.2. Other Development Activities
    • 14.1.3. Safety and Efficacy

15 Genital Warts - The US Market Analysis

  • 15.1. Key Findings
  • 15.2. The United States: Market Outlook
  • 15.3. United States Market Size
    • 15.3.1. Total Market Size of GWs
    • 15.3.2. GWs Market Size by Therapy

16 Market Drivers

17 Market Barriers

18 Market Access and Reimbursement

19 Appendix

  • 19.1. References
  • 19.2. Report Methodology

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

Back to Top
전화 문의